Cargando…

Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы

Primary hyperaldosteronism (PHA) is the most common form of endocrine hypertension. Until recently, the reason for the development of this condition was believed to be the presence of genetic mutations, however, many studies declare that the disease can be polyetiologic, be the result of genetic mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Эристави, С. Х., Платонова, Н. М., Трошина, Е. А.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrinology Research Centre 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761866/
https://www.ncbi.nlm.nih.gov/pubmed/35488752
http://dx.doi.org/10.14341/probl12783
_version_ 1784852758984130560
author Эристави, С. Х.
Платонова, Н. М.
Трошина, Е. А.
author_facet Эристави, С. Х.
Платонова, Н. М.
Трошина, Е. А.
author_sort Эристави, С. Х.
collection PubMed
description Primary hyperaldosteronism (PHA) is the most common form of endocrine hypertension. Until recently, the reason for the development of this condition was believed to be the presence of genetic mutations, however, many studies declare that the disease can be polyetiologic, be the result of genetic mutations and autoimmune triggers or cell clusters of aldosterone-producing cells diffusely located in the adrenal gland at the zona glonerulosa, zona fasculata, zona reticularis, as well as directly under the adrenal capsule. Recently, the actions of autoantibodies to type 1 angiotensin II receptors have been described in patients with renal transplant rejection, with preeclampsia, and with primary hyperaldosteronism. The diagnostic role of antibodies in both forms of PHA (aldosterone-producing adenoma and bilateral hyperaldosteronism) requires clarification. Diagnosis and confirmation of the focus of aldosterone hypersecretion is a multi-stage procedure that requires a long time and economic costs. The relevance of timely diagnosis of primary hyperaldosteronism is to reduce medical and social losses. This work summarizes the knowledge about genetic mutations and presents all the original studies devoted to autoantibodies in PHA, as well as discusses the diagnostic capabilities and limitations of the available methods of primary and differential diagnosis of the disease and the prospects for therapy.
format Online
Article
Text
id pubmed-9761866
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Endocrinology Research Centre
record_format MEDLINE/PubMed
spelling pubmed-97618662023-01-06 Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы Эристави, С. Х. Платонова, Н. М. Трошина, Е. А. Probl Endokrinol (Mosk) Research Article Primary hyperaldosteronism (PHA) is the most common form of endocrine hypertension. Until recently, the reason for the development of this condition was believed to be the presence of genetic mutations, however, many studies declare that the disease can be polyetiologic, be the result of genetic mutations and autoimmune triggers or cell clusters of aldosterone-producing cells diffusely located in the adrenal gland at the zona glonerulosa, zona fasculata, zona reticularis, as well as directly under the adrenal capsule. Recently, the actions of autoantibodies to type 1 angiotensin II receptors have been described in patients with renal transplant rejection, with preeclampsia, and with primary hyperaldosteronism. The diagnostic role of antibodies in both forms of PHA (aldosterone-producing adenoma and bilateral hyperaldosteronism) requires clarification. Diagnosis and confirmation of the focus of aldosterone hypersecretion is a multi-stage procedure that requires a long time and economic costs. The relevance of timely diagnosis of primary hyperaldosteronism is to reduce medical and social losses. This work summarizes the knowledge about genetic mutations and presents all the original studies devoted to autoantibodies in PHA, as well as discusses the diagnostic capabilities and limitations of the available methods of primary and differential diagnosis of the disease and the prospects for therapy. Endocrinology Research Centre 2022-02-18 /pmc/articles/PMC9761866/ /pubmed/35488752 http://dx.doi.org/10.14341/probl12783 Text en Copyright © Endocrinology Research Centre, 2022 https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 License.
spellingShingle Research Article
Эристави, С. Х.
Платонова, Н. М.
Трошина, Е. А.
Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
title Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
title_full Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
title_fullStr Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
title_full_unstemmed Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
title_short Иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
title_sort иммуногенетика первичного гиперальдостеронизма: фундаментальные исследования и их клинические перспективы
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761866/
https://www.ncbi.nlm.nih.gov/pubmed/35488752
http://dx.doi.org/10.14341/probl12783
work_keys_str_mv AT éristavish immunogenetikapervičnogogiperalʹdosteronizmafundamentalʹnyeissledovaniâiihkliničeskieperspektivy
AT platonovanm immunogenetikapervičnogogiperalʹdosteronizmafundamentalʹnyeissledovaniâiihkliničeskieperspektivy
AT trošinaea immunogenetikapervičnogogiperalʹdosteronizmafundamentalʹnyeissledovaniâiihkliničeskieperspektivy